David Meierhofer

Dr. David Meierhofer is the Head of Mass Spectrometry Facility at the Max Planck Institute for Molecular Genetics in Berlin, Germany, a position he has held since March 2012. With a PhD in Genetics from the University of Salzburg (completed December 2005), he previously served as a Senior Post-Doctoral Researcher at MPIMG (2009-2012) and conducted postdoctoral research at the University of California Irvine's Department of Biological Chemistry (2006-2009).

Dr. Meierhofer's primary research interests focus on mitochondrial pathologies, employing proteomic and metabolomic approaches to investigate human mitochondrial dysfunctions. His work centers on understanding the regulatory networks and interplay between proteins and metabolites in mitochondrial disorders, with particular emphasis on post-translational modifications. His expertise spans Mass Spectrometry, Proteomics, Metabolomics, and Energy Metabolism, with significant contributions to understanding mitochondrial involvement in diseases including cancer and diabetes.

Analysis of Dr. Meierhofer's recent publications reveals a strong focus on mitochondrial function in disease contexts, particularly in neurological disorders, liver transplantation, and metabolic diseases. His work frequently employs multi-omics approaches combining proteomics and metabolomics to uncover molecular mechanisms. The research spans fundamental mitochondrial biology to clinical applications, especially in organ transplantation viability assessment and neurodegenerative conditions.

With 189 publications and over 4,500 citations, Dr. Meierhofer has established himself as a significant contributor to mitochondrial research and mass spectrometry applications in biomedical science. His work demonstrates consistent productivity and increasing impact in the field.

As Head of the Mass Spectrometry Facility, Dr. Meierhofer leads a critical resource for proteomic and metabolomic analysis at MPIMG, supporting numerous research groups with advanced analytical capabilities. His facility plays a key role in enabling cutting-edge research on mitochondrial disorders and related pathologies through high-resolution mass spectrometry analysis.